A new mutation in the hepcidin promoter impairs its BMP response and contributes to a severe phenotype in HFE related hemochromatosis.

Marie-Laure Island, Anne-Marie Jouanolle, Annick Mosser, Yves Deugnier, Véronique David, Pierre Brissot, Olivier Loréal

To cite this version:


HAL Id: inserm-00372237
http://www.hal.inserm.fr/inserm-00372237
Submitted on 6 Apr 2009

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Low levels of hepcidin are responsible for the development of iron overload in p.Cys282Tyr HFE related hemochromatosis. Every genetic factor lowering the hepcidin gene expression could contribute to a more severe phenotype in HFE hemochromatosis. Based on this hypothesis, we identified a heterozygous nc.-153 C>T mutation in the hepcidin gene promoter sequence in a patient homozygous for the p.Cys282Tyr HFE mutation who presented massive iron overload, resisting to well conducted iron depletive treatment. Our results demonstrate that the nc.-153 C>T mutation, located within a BMP-RE (Bone Morphogenetic Protein-Responsive Element): i) decreases the transcriptional activity of the hepcidin promoter, ii) alters its IL-6 (Interleukin-6) total responsiveness, and iii) prevents the binding of the SMAD protein complex (1/5/8 and 4) to the BMP-RE. In conclusion, our results suggest that a mutation in the BMP-RE of hepcidin promoter may impact on human iron metabolism.

Key words: hepcidin, BMP, hemochromatosis, iron, gene expression.

©2009 Ferrata Storti Foundation. This is an open-access paper.
Design and Methods

Patient and genetic studies
In 1994, the diagnosis of genetic hemochromatosis was established in a 57 year old man with massive hepatic iron overload (450 µmol of iron/g dry liver weight, n=36) involving mainly hepatocytes and associated to liver fibrosis stage 2-3 in Metavir classification. Iron depletive treatment based on weekly 400 mL phlebotomies was initiated. In 1997, the patient was demonstrated to be homozygous for the p.Cys282Tyr mutation. In 2004 (47 years), 468 venesections had been performed, corresponding to the removal of 85g of iron. However, the patient was always exhibiting abnormal iron parameters with 40 µmol/L for serum iron, 100% for transferrin saturation, and 2,066 µg/L for serum ferritin. In addition, hepatic iron concentration remained very high (close to 300 µmol/g dry liver weight) at MRI.

Serum hepcidin level quantified by Elisa 19 was low (24 µg/L) in comparison to very high (close to 300 µg/L) ferritin. In addition, hepatic iron concentration remained high (650 µmol/g dry liver weight) at MRI.

The patient was always exhibiting abnormal iron parameters with 40 µmol/L for serum iron, 100% for transferrin saturation, and 2,066 µg/L for serum ferritin. In addition, hepatic iron concentration remained very high (close to 300 µmol/g dry liver weight) at MRI. Serum hepcidin level quantified by Elisa was low (24 µg/L) in comparison to very high (close to 300 µg/L) ferritin. In addition, hepatic iron concentration remained high (650 µmol/g dry liver weight) at MRI.

Electrophoretic mobility shift assay
HepG2 cells were incubated with either 10 ng/mL of human BMP9 or 20 ng/mL of human BMP4 for one hour. Then crude nuclear extracts were prepared as described. For gel retardation assays, nuclear extracts (10 µg) were preincubated with 250 ng of poly(dI-dC),poly(dI-dC), used as non-specific competitor DNA, in a binding buffer (10 mM Tris-HCl pH 7.5, 50mM NaCl, 1mM DTT, 1 mM EDTA, 5% glycerol) for 10 min on ice. This mixture was then added to the 32P-end-labeled probe either with or without specific competitor oligonucleotides, and the incubation was carried out for a further 30 min at room temperature. Gel shift assay with purified polyclonal rabbit IgG anti-SMAD4 or anti-SMAD1/5/8 (Santa Cruz) or non-relevant antibody were performed under the same conditions except that the antibodies were preincubated with nuclear extracts for one hour on ice. Complexes were resolved by electrophoresis on prerun Tris-Glycine 5% native polyacrylamide gels. The following chemically synthesized double-stranded oligonucleotides were used as probes and as specific competitors (nucleotide mutation is underlined): BMPRE-wt GCCCTTTTCCGGCCACACC, BMPRE-mut GCCCTTTTCCGGTTGCCACACC.

Results and Discussion

The heterozygous nc -153 C>T was found in hepcidin promoter
In genetic hemochromatosis, iron loading results from abnormally low levels of hepcidin linked to mutations in the hepcidin gene itself or in genes involved in hepcidin expression control, such as the HFE, HJV and TfR2 genes. This prompted us to search for additional mutations in iron regulatory genes in a p.Cys282Tyr homozygous patient presenting a massive iron overload. The sequencing of the HFE gene confirmed the homozygous p.Cys282Tyr mutation and excluded another mutation. In addition, sequencing of HJV, TfR2 and FPN genes were normal. Finally, sequencing of the hepcidin gene led to the identification of a punctual mutation in position -153 from the transcribed start site. This mutation was localized within the BMP-RE as recently proposed, and was found neither in the web databases nor in 200 chromosomes issued from 100 healthy volunteers.
The heterozygous nc.-153 C>T mutation decreases hepcidin promoter transcriptional activity

As described previously,17 the BMP-RE controls human hepcidin promoter transcriptional activity under steady state-condition. In order to assess the effect of the heterozygous nc.-153 C>T mutation on basal hepcidin gene expression, plasmid constructs containing the -1024 bp of the human hepcidin promoter with the wild type or the mutated BMP-RE inserted among the luciferase gene (-1024/BMP-RE wt Hep/Luc and -1024/BMP-RE mut Hep/Luc) were transfected in HepG2 cells. Luciferase activity from the -1024/BMP-RE mut Hep/Luc construct was about 2.4 fold reduced compared to the luciferase activity from the plasmid construct containing the wild type BMP-RE (Figure 1, lanes 1-2), demonstrating that this mutation decreased hepcidin transcriptional activity in basal condition. As this BMP-RE mediates the induction of hepcidin gene expression in response to BMP,17 HepG2 cells were transfected with the -1024/BMP-RE wt Hep/Luc and -1024/BMP-RE mut Hep/Luc) were transfected in HepG2 cells. Luciferase activity from the -1024/BMP-RE mut Hep/Luc construct was about 2.4 fold reduced compared to the luciferase activity from the plasmid construct containing the wild type BMP-RE (Figure 1, lanes 1-2), demonstrating that this mutation decreased hepcidin transcriptional activity in basal condition. As this BMP-RE mediates the induction of hepcidin gene expression in response to BMP,17 HepG2 cells were transfected with the -1024/BMP-RE wt Hep/Luc and -1024/BMP-RE mut Hep/Luc construct and were treated with BMP9 or BMP4 in order to determine if the mutation impaired or not the response to these BMPs.21 As expected, for -1024/BMP-RE wt Hep/Luc construct, the BMP9 treatment increased luciferase activity by about 2.7 fold and BMP4 treatment by 1.8 fold (Figure 1, lanes 1,4,6). By contrast, with the -1024/BMP-RE mut Hep/Luc after BMP9 or BMP4 treatment, there was no change observed for luciferase activities compared to the basal condition (Figure 1, lanes 2,5,7). These results demonstrate that the heterozygous nc.-153 C>T mutation affects the basal hepcidin gene expression and impairs its BMP4/9 response.

Hepcidin gene responsiveness to IL-6 has been recorded decreasing when the BMP-RE or STAT3 binding sites are mutated17 or in SMAD4 –/– mice.22 Accordingly, we found (Figure 1, lanes 8-9), by comparing the impact of IL-6 on wild type and mutated promoter, that the nc.153C>T was critical for IL-6 total responsiveness. However, the mutation did not affect the ability to respond in terms of fold induction, by comparing the ratio between basal and IL-6 stimulated mutated construct (Figure1 lanes 2,9) to the ratio between basal and IL-6 stimulated wild type construct. (Figure 1, lanes 1,8).

To test the severity of the mutation we performed a dose dependent assessment of the BMP4 effect (Figure 2). Whereas we found a dose dependent induction of Luciferase activity from the -1024/BMP-RE wt Hep/Luc construct and no response was observed for the -1024/BMP-RE mut construct, thus demonstrating the critical impact of the mutation on the BMP related signaling. Taken together, these results demonstrate that the nc.-153 C>T mutation affects the basal hepcidin gene expression and impairs its response to BMP4/9 and the IL-6 total responsiveness.

The heterozygous nc.-153 C>T mutation impairs the binding of SMAD1/5/8/4 to the BMP-RE

The BMP-RE DNA region is a potential binding site...
for SMAD1/5/8 transcription factors, which are phosphorylated upon BMP binding to their receptors and migrate to the nucleus associated to SMAD4, to activate transcription of target genes. In order to determine if the heterozygous nc.-153 C>T mutation impaired the formation of a nucleoprotein complex of SMAD1/5/8 with the BMP-RE, an EMSA was performed using nuclear extracts from HepG2 cells treated or not with BMP4 or BMP9 and probes containing the wild type or mutated BMP-RE. A complex was observed using the probe containing the wild type BMP-RE (Figure 3A, lanes 1,3,5; complex I). This complex I is present to a lower extent in nuclear extracts obtained from basal condition compared to those from BMP stimulated cells. The complex I formation was inhibited by using a probe which contained the mutated BMP-RE (Figure 3A, lanes 2,4,6). The specificity of formation of this complex with the probe containing the wild type BMP-RE was demonstrated using unlabeled oligonucleotides containing wild type or mutated BMP-RE in excess. Complex I binding was competed with the wild type BMP-RE used as cold competitor (Figure 3B, lanes 1-4) whereas competitor with the mutated BMP-RE had no effect (Figure 3B, lanes 5-8), thus demonstrating its binding specificity. The lower band was not affected by the wt competitor, demonstrating its unspecificity. To identify the protein content of complex I, HepG2 nuclear extracts were incubated with antibodies against a non-relevant protein as control, SMAD4 or SMAD1/5/8. Supershifts were observed with anti-SMAD4 antibody and anti-SMAD1/5/8 antibody specifically blocked the nucleoprotein complex I formation, thus inducing its disappearance. These results suggest that in HepG2 cells, a nucleoprotein complex containing the SMAD1/5/8/4 proteins is observed with the wild type BMP-RE DNA binding site and that this nucleoprotein complex formation is abrogated by the nc.-153 C>T mutation. Thus, the impairment of SMAD1/5/8/4 binding to the nc.-153 C>T mutated BMP-RE could reduce hepcidin gene expression.

Taken together, our data supports the deleterious impact of the nc.-153 C>T hepcidin promoter mutation. The iron depletive treatment (85g of iron subtracted, including 18g potentially absorbed iron during the whole venesection period, according to Olsson et al. was only partially successful as compared with what can be expected in classical HFE hemochromatosis as well as in juvenile hemochromatosis related to either hepcidin or hemojuvelin gene mutations. These data suggest that: i) the nc.-153 C>T mutation may have an additive effect to the homozygous p.Cys282Tyr mutation, which remains to be characterized and, ii) that the addition of an iron chelator treatment could be relevant both to potentiate iron elimination and to limit venesection-related iron absorption.

Our overall results suggest that mutations in BMP-RE of hepcidin promoter may alter iron homeostasis, contributing to the increase in the iron burden in HFE related hemochromatosis.

**Authorship and Disclosures**

MLI designed and performed experiments, analyzed data and wrote the manuscript. PB diagnosed the patient and participated in writing the manuscript. AMJ and AM performed sequencing and analyzed data. VD and YD coordinated the study in healthy volunteers and participated in writing the manuscript. OL initiated the study, analyzed data and wrote the paper.

The authors reported no potential conflicts of interest.
References


